The Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with XTANDI® (enzalutamide), plus abiraterone acetate and prednisone as compared to treatment with abiraterone acetate and prednisone alone, did not meet its primary endpoint of improvement in progression-free survival (PFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC) whose prostate-specific antigen (PSA) has previously progressed on XTANDI.
I'm thinking this may be good news for Zenith. This assumes that the new 1b trial we are undertaking will show that benefits will ensue if ZEN-3694 is taken in conjunction with XTANDI. Pfizer may then say "we'll buy it".
Thoughts?
http://www.businesswire.com/news/home/20161214006177/en/
masila
